Division of Diagnostic Pathology, Shizuoka Cancer Center, Sunto, Shizuoka, Japan.
Brain Tumor Pathol. 2011 Apr;28(2):127-35. doi: 10.1007/s10014-011-0022-8. Epub 2011 Feb 18.
Expression of the O(6)-methylguanine-DNA methyltransferase (MGMT) gene has been shown to correlate with clinical outcomes in patients with glioblastoma multiforme treated with alkylating agents. We evaluated MGMT protein expression in 53 primary glioblastomas by the immunohistochemistry (IHC) and analyzed the correlation between results of immunostaining and patient outcomes. There were 28 MGMT-immunopositive and 25 negative glioblastomas. Patients with MGMT-immunonegative glioblastomas showed significantly longer progression-free survival (PFS) (P = 0.0032), but no statistically significant benefits on overall survival (OS) (P = 0.0825) were shown. In 41 glioblastomas treated with temozolomide (TMZ) therapy (MGMT-immunopositive: n = 22, negative: n = 19), both PFS and OS were significantly better in MGMT-immunonegative glioblastomas. (PFS: P = 0.0015, OS: P = 0.0384). We conclude that MGMT expression on immunohistochemistry (IHC) correlates with outcomes in patients with primary glioblastoma receiving TMZ and suggest the use of MGMT-IHC as a surrogate marker for predicting tumor chemosensitivity.
O(6)-甲基鸟嘌呤-DNA 甲基转移酶（MGMT）基因的表达已被证明与接受烷化剂治疗的多形性胶质母细胞瘤患者的临床结果相关。我们通过免疫组织化学（IHC）评估了 53 例原发性胶质母细胞瘤中的 MGMT 蛋白表达，并分析了免疫染色结果与患者预后之间的相关性。有 28 例 MGMT 免疫阳性和 25 例阴性的胶质母细胞瘤。MGMT 免疫阴性胶质母细胞瘤患者的无进展生存期（PFS）明显延长（P = 0.0032），但总生存期（OS）无统计学意义的改善（P = 0.0825）。在接受替莫唑胺（TMZ）治疗的 41 例胶质母细胞瘤中（MGMT 免疫阳性：n = 22，阴性：n = 19），MGMT 免疫阴性胶质母细胞瘤的 PFS 和 OS 均明显更好。（PFS：P = 0.0015，OS：P = 0.0384）。我们得出结论，MGMT 在免疫组织化学（IHC）上的表达与接受 TMZ 治疗的原发性胶质母细胞瘤患者的结果相关，并建议将 MGMT-IHC 用作预测肿瘤化疗敏感性的替代标志物。
